Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

and in the ROW at year end.

During the fourth quarter of 2007, the Company received six generic product approvals in the U.S. from the FDA, including tentative approvals, and 39 approvals, representing 28 molecules, from regulatory bodies in Europe and in the ROW.

Proprietary Products

The Company currently has an extensive proprietary clinical development program that includes four products in Phase III studies and three New Drug Applications pending at the FDA.

Selling, General and Administrative

The Company's SG&A expenses for the quarter and year ended December 31, 2007 totaled $207 million and $764 million, respectively. SG&A for 2007 included a charge of $15.3 million for litigation related to the Ovcon(R) oral contraceptive product.

Interest Expense/Income and Other Income

During 2007, the Company recorded $159 million of interest expense, almost all of which is related to interest on the debt incurred in connection with the PLIVA acquisition. In addition, during 2007, the Company recorded interest income of $33 million and other income of $21 million.

Stock-Based Compensation

During 2007, the Company recorded stock-based compensation expenses of $27.8 million, or $0.17 per share. For the fourth quarter of 2007, the Company recorded stock-based compensation expenses of $4.4 million, or $0.03 per share. The impact of stock-based compensation for the year and quarter ended December 31, 2007 is allocated among cost of sales, SG&A and R&D.

Tax Rate

The Company's tax rate for the quarter and year ended December 31, 2007 was 28.1% and 31.1%, respectively. The tax rate for the year includes a one- time $9.6 million benefit from a reduction in deferred income taxes as a result of Germany's enactment of a lower corporate income tax rate.

Balance Sheet

The Company's cash, cash equivalents and marketable securities totaled approximately $551 million. At December 31, 2007, the Comp
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... your ear could improve the health of your heart, ... of Leeds used a standard TENS machine like those ... to the tragus, the small raised flap at the ... ear canal. , The stimulation changed the influence of ... nervous signals that can drive failing hearts too hard. ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
(Date:8/19/2014)... Pa. , Aug. 19, 2014 A ... has been nominated for a Centers for Disease Control ... addressing a major public health concern. ... System, is one of a team of researchers nominated ... Charles C. Shepard Science Award for Data Methods and ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Health-focused social networks,blogs, wikis and community sites ... can be their biggest opportunities. A marketing,executive ... increasing,importance of reputation monitoring and management in ... Generated Content and Enhancing its Impact,on Your ...
... EASTON, Mass., Dec. 11 Pressure BioSciences, Inc. (Nasdaq: ... Omni International ("Omni") today announced that they have entered ... Under the terms of the Agreement, the companies will: ... competitive information; (2) co-promote certain products at industry trade ...
... adults may be familiar with the,tetanus and diphtheria booster ... a booster shot that protects adolescents and adults from,whooping ... Listen to this report from ... Registered journalists can access video, audio, text, ...
Cached Biology Technology:Exclusive Conference on Managing Your Online Brand: Shaping the Noise from the Blogosphere 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... a chili pepper causes a burning spiciness that is ... the chili pepper,s effect are using their findings to ... pain, which can be caused by inflammation or other ... is being tested in clinical trials, in ACS, ... colleagues explain that decades ago, scientists had pegged a ...
(Date:8/20/2014)... (August 20, 2014) Women who are poor experience ... infants with elevated levels of the stress hormone, ... in life, according to a new research from the ... recently in the American Journal of Human Biology ... and relate it directly to the socioeconomic status of ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2CU Denver researcher shows economic disparities impact infant health 2
... Ohio, June 27, 2012 Expertise in fluid mechanics at ... research center designed to help physicians better diagnose and treat ... shoulders. Chiari malformation is a disorder of the neurologic ... spinal fluid. UA engineers are able to probe the ...
... is a very small unit, even smaller than the nano ... Alonso has devoted himself to studying green algae of this ... to the area beyond the Nervin estuary. This has enabled ... species that until now had not been catalogued in these ...
... Anatolian Neolithic" is the name of a new multinational ... Commission for the next four years. It is classified ... EU Marie Curie Actions program, which allows young scientists ... A basic requirement for funding is that the researchers ...
Cached Biology News:When does a headache need an engineer to fix it? 2When does a headache need an engineer to fix it? 3A nanoscopic look at the estuary's green algae 2A nanoscopic look at the estuary's green algae 3Mainz University coordinates new EU project on the origins of human settlement 2Mainz University coordinates new EU project on the origins of human settlement 3
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Human PDGF R beta MAb (Clone # PR7212)...
... Ambion's ActivePro In Vitro ... an E.coli lysate, synthesizes ... as well as proteins ... than competing kits. This ...
Biology Products: